The record
| Class | anti aging |
|---|---|
| Also known as | FOX04-DRI, FOXO4-D-Retro-Inverso, Senolytic peptide |
| Chain length | - |
| Molecular weight | 5,358.0 Da |
| Half-life | Short plasma half-life but extended due to D-amino acids |
| Route | SC or IV (research) |
| Studied for | - |
| Research use | Senescent cell clearance; Aging research; Tissue regeneration studies |
| What has been shown | Selective senolysis in aged mice; Improved fur density and fitness; Restored renal function; Neutralized chemotoxicity |
| How it works | D-Retro-Inverso peptide that disrupts FOXO4-p53 interaction in senescent cells. In senescence, FOXO4 binds p53 at DNA-SCARS, preventing apoptosis. FOXO4-DRI: (1) Penetrates cells via CPP domain, (2) Competitively binds p53, (3) Displaces FOXO4, (4) Releases p53 for nuclear exclusion, (5) p53 translocates to mitochondria, (6) Activates intrinsic apoptosis. Selective for senescent cells due to high |
| Patent status | Erasmus Medical Center |
| Regulatory status | Research only - NOT approved |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Proteostasis / Cellular Cleanup (affection, 37%)
- Senescence Modulation (Research) (affection, 79%)
- Age-related immune decline (illness, 40%)
- Cancer prevention (illness, 40%)
- Immune deficiency (illness, 40%)
- Tissue regeneration (illness, 40%)